Johnson & Johnson
3Q Revenues: $22.5 billion (+5%)
3Q Earnings: $2.7 billion (-38%)
YTD Revenues: $42.6 billion (+4%)
YTD Earnings: $10.6 billion (-66%)
Comments: Growth in the quarter was driven by Darzalex, up 21% to $3.0 billion; Erleada, up 25% to $790 million; other oncology, with sales of $250 million; and Carvykti in oncology, up 88% to $286 million; Tremfya in immunology, up 13% to $1.0 billion; Spravato in neuroscience, up 55% to $284 million, and Opsumit in pulmonary hypertension, up 17% to $571 million. Growth was offset by declines for Stelara, down 7% to $2.7 billion and Simponi down 18% to $516 million.